Enterprises ImportFab Inc. has been acquired by Labomar S.p.A
Labomar S.p.A., a leading company in the research, development and production of food supplements, medical devices and foods for specific medical and cosmetic purposes, has acquired Enterprises ImportFab Inc., a Canadian firm based in Montréal that operates in the North American pharmaceutical, cosmetic and nutraceutical market. The operation has been carried out in partnership with SIMEST that will participate in the acquisition and will hold a minority share of the Canadian company.
ImportFab is a well-established contract manufacturer, specializing in the manufacturing and packaging of semi-solid and liquid products for the pharmaceutical, cosmetic and nutraceutical market. With 30 years of experience, the company has a very strong customer base. ImportFab is accredited by Health Canada and the US FDA.
Headquartered in Italy, Labomar is a reliable partner with over twenty years experience offering its customers effective, quality, front-line solutions in the field of food supplements, medical devices, cosmetics, as well as foods for special medical purposes. Labomar is engaged in production on behalf of third parties, providing a complete service ranging from selection of the raw materials to delivery of the finished product. The heart and soul of its activity is the research and development department, guaranteeing constant innovation and quality.
Oaklins' team in Canada advised the seller, contacted over 100 potential buyers through its international teams and negotiated the terms of the transaction. Oaklins' team in Italy introduced Labomar and assisted throughout the process.
Sylvain Renzi
Founder, Enterprises ImportFab, Inc.
Talk to the deal team
Related deals
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn moreMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn more